HCW 9302
Alternative Names: HCW-9302Latest Information Update: 04 Sep 2026
At a glance
- Originator HCW Biologics
- Class Anti-inflammatories; Immunotherapies; Interleukins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Phase I Alopecia areata
- Preclinical Atopic dermatitis; Autoimmune disorders
Most Recent Events
- 02 Sep 2026 HCW Biologics has patent protection for broad compositions, nucleic acids encoding for HCW 9302 and the vectors comprising these, and method of treating other autoimmune diseases in USA
- 02 Sep 2026 HCW Biologics receives patent allowance for the "claims directed to use of HCW 9302 to treat alopecia areata" in USA
- 15 Aug 2026 Preclinical trials in Atopic dermatitis in USA (Parenteral) prior to August 2026